BriaCell Therapeutics Corp Warrant
BCTXW
BCTXW was delisted on the 26th of February, 2026.
8 hedge funds and large institutions have $3.29M invested in BriaCell Therapeutics Corp Warrant in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and closing their positions.
14% more funds holding
Funds holding: 7 → 8 (+1)
0.23% more ownership
Funds ownership: 9.73% → 9.96% (+0.23%)
23% less capital invested
Capital invested by funds: $4.26M → $3.29M (-$966K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
80% less call options, than puts
Call options by funds: $341K | Put options by funds: $1.67M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFM
Privium Fund Management
Amsterdam,
Netherlands
|
+$106K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$1.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KJHP
K.J. Harrison & Partners
Toronto,
Ontario, Canada
|
-$10.1K |
| 2 |
M
Murchinson
Toronto,
Ontario, Canada
|
-$9.43K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.48K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
M
1
Murchinson
Toronto,
Ontario, Canada
| $1.08M | -$9.43K | -4,044 | -0.8% |
|
|
AC
2
Armistice Capital
New York
| $772K | – | – | – |
|
|
PFM
3
Privium Fund Management
Amsterdam,
Netherlands
| $622K | +$106K | +45,306 | +17% |
|
|
KJHP
4
K.J. Harrison & Partners
Toronto,
Ontario, Canada
| $581K | -$10.1K | -4,340 | -2% |
|
|
RAM
5
Redmond Asset Management
Henrico,
Virginia
| $144K | – | – | – |
|
|
ZCA
6
Zeke Capital Advisors
Berwyn,
Pennsylvania
| $92.7K | – | – | – |
|
|
7
UBS Group
Zurich,
Switzerland
| $2.97K | -$3.48K | -1,492 | -51% |
|
|
8
Bank of America
Charlotte,
North Carolina
| $972 | +$1.1K | +472 | New |
|
BCTXW Hedge Fund Activity: Q4 2022 in Review
8 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in BriaCell Therapeutics Corp Warrant (BCTXW) for Q4 2022, worth a combined $3.29M — down 23% from $4.26M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new BCTXW positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Privium Fund Management, adding an estimated $106K. The largest seller was K.J. Harrison & Partners, cutting an estimated $10.1K.
- 8 institutional investors held BriaCell Therapeutics Corp Warrant (BCTXW) as of Q4 2022, up from 7 in Q3 2022.
- Funds reported $3.29M of BriaCell Therapeutics Corp Warrant stock for Q4 2022, down 23% quarter-over-quarter.
- 1 fund opened new BriaCell Therapeutics Corp Warrant positions in Q4 2022 and 0 closed out, a net change of +1 holder.
- The largest BriaCell Therapeutics Corp Warrant buyer in Q4 2022 was Privium Fund Management, an estimated $106K added.
- The largest BriaCell Therapeutics Corp Warrant seller in Q4 2022 was K.J. Harrison & Partners, an estimated $10.1K sold.
Based on aggregated 13F filings for Q4 2022.